Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting

NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) — Obagi Medical, a number one innovator in physician-delivered skincare and aesthetic options and a part of Waldencast plc (NASDAQ: WALD), at the moment introduced new information shared on the latest American Society for Dermatologic Surgical procedure (ASDS) Annual Assembly, held November 13-16, 2025 in Chicago, Illinois.

Pivotal FDA examine comparability of two hyaluronic acid fillers for midface augmentation and related enchancment within the look of the nasolabial folds led to Obagi hyaluronic acid within the prime 10 abstracts, introduced by Dr. Sue Ellen Cox:

“As an investigator on this pivotal examine, I used to be happy that the information was acknowledged as one of many prime 10 abstracts and chosen for an oral presentation,” stated Dr. Sue Ellen Cox. “The information highlights the compelling outcomes of the Obagi^® sayfa^® ChIQ™ pivotal examine and demonstrates the product’s potential to ship excessive satisfaction to sufferers looking for long-lasting, natural-looking outcomes.”

This pivotal, randomized, multicenter examine in contrast the effectiveness and security of two hyaluronic acid fillers for restoring midface quantity and bettering the nasolabial fold. The examine demonstrated non-inferiority of Obagi® Saypha® ChIQ™ ** in comparison with Juvéderm Voluma® XC, with excessive affected person satisfaction and sturdy security throughout pores and skin varieties.

Extra summaries:

Obagi Scalp Serum 3-month interim outcomes

Interim information from the continuing Obagi Nu-Cil® BioStim™ Scalp Serum examine highlights enhancements in scalp well being and hair look after three months.

A scientific framework for evaluating crosslinking applied sciences for hyaluronic acid fillers

This analysis introduces a brand new framework for evaluating HA fillers and showcases the industry-leading capabilities of the Obagi line of injectables.

“Obagi Medical’s dedication to advancing dermatology science and driving innovation is mirrored within the information shared with our skincare and injectable portfolio on the latest ASDS assembly,” stated Drew Wonderful, US Basic Supervisor, Skilled Channel. “New merchandise with confirmed high quality, a well-established security profile and excessive affected person satisfaction are important to increasing the aesthetic injectables market. The number of the Obagi® Saypha® ChIQ™ abstract as one of many prime 10 for oral presentation highlights the robust information supporting the brand new Obagi injectable.”

Nu-Cil® BioStim™ Scalp Serum extends Obagi’s 35 years of experience in pores and skin well being and management in medical innovation by making use of his “pores and skin first” philosophy to the scalp by the BioStim™ Complicated. The BioStim™ Complicated makes use of patented expertise, powered by a synergistic mix of clinically confirmed actives, together with biotin, amino acids and peptides, along with 18 important vitamins, B nutritional vitamins and phytoactives. These lively elements promote scalp well being, strengthen hair follicles and strengthen strands from the basis.

Obagi® Saypha® ChIQ™, developed by Croma-Pharma GmbH, makes use of patented MACRO Core expertise that creates a secure 3D HA matrix designed to supply natural-looking outcomes with industry-leading capabilities together with excessive HA content material at injection, constant gel distribution, and a predictable injection pressure and swelling profile. Obagi® Saypha® ChIQ™ is at the moment below evaluation for FDA approval. Obagi Medical’s Obagi® Saypha® MagIQ™ was just lately accredited by the FDA.

About Obagi Medical
Obagi Medical is a number one, superior skincare line, rooted in analysis and pores and skin biology, with a legacy of greater than 35 years of expertise. Initially recognized for his or her management within the therapy of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical merchandise are designed to handle a wide range of pores and skin considerations together with untimely growing older, photodamage, pores and skin discoloration, pimples and solar injury. Because the quickest rising skilled skincare model within the US by 2024*, Obagi Medical empowers people to attain wholesome, lovely pores and skin. Extra details about Obagi is accessible on the model’s web site, https://www.obagi.com.

*Ranked among the many prime 10 skilled skincare manufacturers within the US, in accordance with Kline’s 2024 World Skilled Pores and skin Care Sequence (China, Europe and US)
** Obagi® Saypha® ChIQ™ is at the moment below evaluation for FDA approval

About Waldencast
Based by Michel Brousset and Hind Sebti, Waldencast’s ambition is to construct a world best-in-class magnificence and wellness platform by growing, buying, accelerating and scaling acutely aware, high-growth, purpose-driven manufacturers. Waldencast’s imaginative and prescient is basically supported by its brand-driven enterprise mannequin that ensures proximity to its prospects, enterprise flexibility and market responsiveness, whereas sustaining the distinctive DNA of every model. Step one in realizing her imaginative and prescient was the enterprise mixture with Obagi Medical and Milk Make-up. As a part of the Waldencast platform, the manufacturers will profit from the operational scale of a multi-brand platform; the experience in managing world magnificence manufacturers at scale; a balanced portfolio to restrict class fluctuations; lighting effectivity of property; and the market responsiveness and velocity of entrepreneurial indie manufacturers. For extra info please go to: https://ir.waldencast.com/.

About Croma-Pharma GmbH
Based in 1976, Croma-Pharma GmbH is a family-owned world participant within the subject of minimally invasive aesthetic drugs. The corporate, headquartered in Leobendorf, Austria, specializes within the industrial manufacturing of hyaluronic acid syringes and distributes its merchandise in additional than 80 nations. Croma gives an intensive vary of aesthetic merchandise, together with HA fillers, botulinum toxin, PDO threads and biostimulators. Saypha(R) is a registered trademark of Croma-Pharma GmbH, used below license. Extra info athttp://www.croma.at.

Ahead-Trying Statements
This press launch incorporates sure forward-looking statements inside the that means of the federal securities legal guidelines, together with statements relating to the deliberate launch of Saypha® MagIQ™, the power to acquire FDA approval for Saypha® and Waldencast’s progress methods, together with Obagi Medical and Novaestiq. These forward-looking statements are typically recognized by the phrases “estimates,” “tasks,” “expects,” “anticipates,” “predicts,” “plans,” “intends,” “believes,” “seeks,” “could,” “will,” “would,” “ought to,” “future,” “proposes,” “purpose,” “goal,” “goal,” “outlook” and variations of those phrases or related expressions (or the unfavorable variations of such phrases or expressions) are supposed to be forward-looking statements. These forward-looking statements should not ensures of future efficiency, circumstances or outcomes and contain numerous recognized and unknown dangers, uncertainties, assumptions and different necessary elements, lots of that are past the management of Waldencast, Obagi Medical and Novaestiq, which may trigger precise outcomes or outcomes to vary materially from these mentioned within the forward-looking statements. Essential elements that might have an effect on precise outcomes or outcomes embrace, however should not restricted to: (i) the lack to acquire FDA approval for Saypha® ChIQ merchandise, (ii) the success of business launches, (iii) the overall impression of geopolitical occasions, together with the impression of present wars, conflicts and different hostilities, (iv) basic financial and market circumstances, gross sales forecasts and different details about the attainable or assumed future working outcomes of Waldencast or our efficiency, (v) modifications basically financial circumstances, (vi) the impression of worldwide commerce or trade restrictions, the imposition of latest or elevated tariffs, fluctuations in overseas forex trade charges, (vii) that the worth of Waldencast’s securities could also be unstable because of a wide range of elements, together with the lack of Waldencast, Obagi Medical or Novaestiq to execute their enterprise plans, and (viii) the power to implement Waldencast’s strategic initiatives and its present services of Obagi Medical to proceed to innovate, anticipate and reply to market traits and modifications in shopper preferences. The foregoing record of things is just not exhaustive. You need to fastidiously contemplate the foregoing elements and the opposite dangers and uncertainties described within the “Danger Elements” part of Waldencast’s Annual Report on Kind 20-F for the 12 months ended December 31, 2024 filed with the SEC on March 20, 2025, or in different paperwork which may be filed or furnished by Waldencast with the SEC now and again. These paperwork determine and deal with different necessary dangers and uncertainties that might trigger precise occasions and outcomes to vary materially from these within the forward-looking statements. Ahead-looking statements converse solely as of the date on which they’re made. Readers are cautioned to not place undue reliance on forward-looking statements, and Waldencast assumes no obligation and doesn’t intend to replace or revise these forward-looking statements, whether or not on account of new info, future occasions or in any other case.

Contacts

Buyers
ICR
WaldencastIR@icrinc.com

Media
ICR
WaldencastPR@icrinc.com